Group items tagged

Antiviral Drugs Market by Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, and Protease Inhibitors), Type (Generic Drugs and Branded Drugs), and Application (HIV, Hepatitis, Herpes, and Influenza) - Global Opportunity Analysis and Industry Forecast, 2018-2025

The global film dressing market size is anticipated to reach USD 2,165.41 million by 2030, registering a CAGR of 4.54% during the forecast period, according to a new report by Grand View Research, Inc.

The global clinical trial investigative site network market size is expected to reach USD 12.5 billion by 2030, registering a CAGR of 6.0% over the forecast period, according to a new report by Grand View Research, Inc.

The global medical terminology software market size is expected to reach USD 2.34 billion by 2030, registering a CAGR of 10.1% during the forecast period, according to a new report by Grand View Research, Inc.

Alphega Pharmacy Oncology Support Programme allows community pharmacists from six European countries to enhance support and guidance they provide to cancer patients. The programme aims to help upskill pharmacists and their teams to provide more expert advice to patients living with cancer, raising their profile in the community as key healthcare providers. Enhancing knowledge amongst community pharmacists about cancer treatment and its side effects is vital as cancer cases are set to increase if current trends continue. The programme covers practical help topics, such as oral care, nutrition advice and skin, hair and nail care among others, helping patients to get more of the support they need because community pharmacists are easily accessible, rather than needing to book a GP or consultant appointment. With rates of cancer forecast to rise throughout Europe , and cancer patients likely on average to visit hospital less often, community pharmacists are well-placed to look to support cancer patients with managing the side-effects of their treatment.

A new study published in The Lancet has revealed that a total of 1.7 million people could be living with dementia in England and Wales by 2040. The research highlighted increasing numbers of people who will suffer from Alzheimer's. The disease would massively increase the burden on the healthcare system. The research was led by University of College London (UCL). Lead researcher, Dr Yuntao Chen said, "It is shocking to think that the number of people living with dementia by 2040 may be up to 70 per cent higher than if dementia incidence had continued to decline. "Not only will this have a devastating effect on the lives of those involved but it will also put a considerably larger burden on health and social care than current forecasts predict.

American biotechnology company Novavax said on Monday (February 28) it would pursue full approval of its Covid-19 vaccine in the second half of this year and forecast total revenue of between $4 billion and $5 billion for 2022. "We expect to gain additional authorizations where we have already filed, including in the US. We will pursue full approval of our vaccine including filing our BLA (biologics license application), in the second half of 2022," CEO Stanley Erck said during a post-earnings call. Novavax late last month filed for emergency use authorization of the shot in U.S. adults, a much-awaited step following months of struggles with development and manufacturing problems. Novavax said it has completed delivery of around nine million vaccine doses to Indonesia, 6 million to Australia and two million to South Korea and expects to supply 69 million doses to Europe in the first half of this year.

Pfizer said on Tuesday it will pay $11.6 billion to buy Biohaven Pharmaceuticals, making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs. The boards of both companies have approved the deal, they said. Biohaven shares jumped 70 per cent to $141.31, while Pfizer was up slightly at $48.83. Pfizer is flush with cash from a once-in-a-lifetime surge in revenue from Covid-19 vaccines and therapeutics and has said it is looking to buy companies or drugs that could add at least $25 billion in annual sales by the end of the decade. "The CGRP oral medications, though still somewhat newer entrants in a deeply entrenched space, continue to make steady inroads in disrupting the broader migraine market in the U.S.," said BioHaven chief executive Vlad Coric. Biohaven forecast Nurtec sales of $825 million to $900 million in 2022. Pfizer said it expects the pills to eventually overtake the shots.

Market Industry Reports (MIR) has published a new report titled "IV Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2030." According to the report, the global IV Equipment market is estimated to be around US$ 10.0 Bn in 2017. It is anticipated to grow at a substantial CAGR from 2019 to 2030.

The study estimates the Vascular Graft market size for 2018 and projects its demand till 2023. In the primary research process, various sources from both demand side and supply side were interviewed to obtain qualitative and quantitative information for the report. Primary sources from the demand side include research scientists, Vascular Graft specialists, laboratory technicians, and R&D professionals of pharmaceutical and biotechnology companies and academic research institutes.

The Veterinary Software Report Provide SWOT analysis to understand Strengths, Weaknesses, Opportunities, and Threats of the Veterinary Software industry along with competitive Analysis. Along with, analysis of upstream raw materials and downstream consumers are also conducted in Veterinary Software research study. Global Veterinary Software market influences various other factors such as globalization, improvements in trade and income, and commercialization to enhance extensive growth.

The clinical decision support systems market is projected to reach USD 1,752.0 Million by 2023 from USD 901.0 Million in 2017, at a CAGR of 11.8%. Factors such as government support & initiatives, growing incidence of medication errors, rising prominence & usage of big data and mhealth tools, high returns on investment for CDSS solutions, and growing adoption of cloud computing in healthcare are driving the growth of this market.

he global multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.33 Billion in 2018, at CAGR of 7.5%. Multiplex assays enables the simultaneous detection of multiple analytes in a single run/cycle of the assay. The use of multiplex assays in companion diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays are driving the growth of the market.

The global Contrast Media Market size is expected to reach USD 7.2 billion by 2028, according to a new report published by Grand View Research, Inc.

The global catheters market size was valued at USD 45.26 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.4% from 2021 to 2028.

The global point of care diagnostics and testing market size was valued at USD 27.66 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 3.25% from 2021 to 2028.

The global infection control market size was valued at $32,613.75 million in 2020, and is projected to reach $38,616.77 million by 2028, registering a CAGR of 3.0% from 2021 to 2028.